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EIGHTEEN YEARS OF PHARMACOGENETICS
Pharmacogenetics and personalized prescription have long and overlapping histories but they were
probably born with the DNA microarray technology which allows parallel genetic testing.1 In 1997,
Science defined “personalized prescription” as “tailoring drugs to a patient’s genetic makeup” and
predicted that personalized prescription would “soon” reach clinical practice. The end of the race for the
Human Genome in 2000 led to further hype. The most widely circulated US news magazine, Time,
predicted that the generalized use of personalized prescription would begin in 2015, while JAMA
predicted 2020. Now that it’s 2015, are we any closer to using pharmacogenetic testing to guide our
pharmacological treatments? The answer is obviously, “No”. “No” both in child psychiatry and medicine
in general.
How is it possible that personalized prescription has not reached adulthood in 2015 following
those rosy predictions? The answer lies in two facts: 1) the process of implementing pharmacogenetic
testing under the auspices of the Food and Drug Administration (FDA) was flawed, and 2) personalizing
prescription is even more complex than pharmacogenetic testing, as the story of atomoxetine
demonstrates.
THE FDA AND PHARMACOGENETICS
In the 1990s, the FDA implemented guidelines to encourage the introduction of pharmacogenetic
testing in the clinical environment and defined the cytochrome P450 2D6 (CYP2D6) as a “valid
biomarker.” The pharmaceutical companies felt threatened; new drugs would be subjected to the
complications of pharmacogenetic testing and/or potentially smaller markets. CYP2D6 is the main
metabolic enzyme for many psychiatric drugs but, due to the unpredictable twists of evolution, it is absent
in 7% of Caucasians. They have two non-functional CYP2D6 alleles and are called poor metabolizers
(PMs). On the other hand, approximately 1.5% of US Caucasians and African-Americans have 3 or more
active alleles, and produce more than normal quantities of CYP2D6 in their livers. They are called
ultrarapid metabolizers (UMs). To avoid problems, the pharmaceutical companies decided to eliminate
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from their pipelines drugs heavily dependent on CYP2D6 for their metabolism; atomoxetine was one of
the last ones marketed. Its manufacturer had to meet the FDA guidelines and demonstrate that
atomoxetine was safe for CYP2D6 PMs.
COMPLEXITIES OF PERSONALIZED PRESCRIPTION AND PHARMACOGENETICS
FDA guidelines do not sufficiently account for the complexity of the clinical environment, as PM
status can be explained by different mechanisms. Obviously, genetics may cause CYP2D6 PM status.
Secondly, clinicians can produce PM status by prescribing powerful CYP2D6 inhibitors, such as
paroxetine or fluoxetine, which can cause patients with normal CYP2D6 activity, called extensive
metabolizers (EMs), to behave as if they have no CYP2D6 activity. This exemplifies CYP2D6 PM status
explained by environmental factors. Lastly, for some CYP2D6 drugs partly eliminated by the kidney,
such as risperidone, renal insufficiency can account for individuals who look like PMs; in this case a
personal factor has produced a CYP2D6 PM status.
Therefore, personalized prescription should include genetic as well as environmental (e.g., comedications, herbal medicines, smoking, foods, beverages) and personal (e.g., age, gender, ethnicity,
illness) variables.2 To further complicate things, personalized prescription can be expressed as
personalizing dosing and/or drug selection, and should consider pharmacokinetic and pharmacodynamic
mechanisms which influence both the safety and efficacy of drugs. In the case of atomoxetine, one of
these pieces in the complex puzzle of personalized prescribing was ignored, namely, the width of its
therapeutic index (or window).3
The best way of implementing personalized dosing2 is by combining pharmacogenetics with blood
levels, which pharmacologists call therapeutic drug monitoring (TDM). Unfortunately for atomoxetine, its
data is hampered since 1) all the related pharmacogenetic studies focused on CYP2D6 PMs and safety
during the randomized clinical trials (RCTs), as required by the FDA; and 2) the published TDM data
focuses on peak concentrations, which are harder to interpret than the steady-state trough levels studied by
the traditional TDM studies in the clinical environment.
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ATOMOXETINE AND CYP2D6 PMs
In pharmacokinetic studies, at steady state, after twice-daily dosing, the mean steady-state plasma
concentrations were approximately 10-fold higher in CYP2D6 PMs than in CYP2D6 EMs. However,
these pharmacokinetic differences had no relevance to adverse drug reactions (ADRs) during the RCTs.
The most comprehensive ADR report4 compared 87 CYP2D6 PMs and 1239 CYP2D6 EMs. Despite a
lower mean dose in PMs, they demonstrated, when compared with EMs, marginally better efficacy in
response rate (85% vs. 82%, p=0.56, odds ratio, OR calculated with article data by this author=1.2, 95%
confidence interval, CI, 0.79-2.1) and comparable ADR profiles with a difference in discontinuation due
to ADRs of 6% vs. 2% (OR=2.5, 1.1-5.6), which did not reach significance (p=0.08).
Atomoxetine was marketed and the US prescribing information (or package insert) recommends
lower doses for CYP2D6 PMs or those taking CYP2D6 inhibitors, but it makes no comment on the need
for CYP2D6 genotyping before prescribing atomoxetine. Thus, child psychiatrists do not need to worry
about CYP2D6 genotyping when prescribing atomoxetine.
ATOMOXETINE AND CYP2D6 UMs
Atomoxetine follows linear kinetics. This means that the relationship between concentration doses
is stable and very predictable. The pharmaceutical company should have focused not on atomoxetine
ADRs in CYP2D6 PMs, but on the lack of efficacy in CYP2D6 UMs. As CYP2D6 PMs have a 10-fold
increase in atomoxetine levels with no relevant increase in ADRs, this proves that atomoxetine is a very
safe drug with a wide therapeutic index. Prior pharmacological experience indicates that in drugs with a
wide therapeutic index, one needs to focus on UMs, who may not have sufficient drug levels at the usual
recommended dosages.3
Table 1 describes the response rate at the endpoint of the acute treatment phase5 and uses these
response rates to make predictions. To increase the response rate of EMs in the acute phase from the 60%
obtained to the 80% seen in CYP2D6 PMs, one needs to get the same atomoxetine levels in CYP2D6
EMs as in PMs. As atomoxetine follows linear kinetics, one would have to increase the EM dose 10-fold
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to get approximately the same mean plasma concentration as the PMs in the RCTs. Table 1 indicates that
up to 20% of CYP2D6 EMs were underdosed in the RCTs, which may have contributed to a 9% increase
in dropouts due to lack of efficacy in CYP2D6 EMs.
In the RCTs, CYP2D6 UMs were included in the CYP2D6 EM group and probably were heavily
overrepresented in the group lacking efficacy. Assuming that atomoxetine follows linear kinetics and that,
as in other CYP2D6 drugs, UMs had an increase in metabolism by at least a factor of 2 when compared
with EMs, one needs to conclude that, during the RCTs, CYP2D6 UMs probably had less than half the
atomoxetine levels as EMs, and approximately 20 times less than CYP2D6 PMs. If this is correct, UM
doses 20 times higher than used in the RCTs would provide the 80% response rate seen in CYP2D6 PMs.
New studies using CYP2D6 genotyping and TDM are needed to establish whether or not higher
atomoxetine doses are required for CYP2D6 UMs (1.5% in US Caucasians and 2.0% in AfricanAmericans) and possibly in CYP2D6 EMs with ≥2 more active alleles (respectively, 36.4% and 18.3%)
who may not respond to recommended doses. Unfortunately, the independent investigators testing this
hypothesis would have to start from scratch, as CYP2D6 UM response information is absent and
atomoxetine TDM data is limited. The company completed a study of two-times higher doses of nonresponders that was negative, but was not guided by TDM or CYP2D6 genotyping. The author proposes
that after CYP2D6 genotyping, those subjects with ≥2 active alleles, which in total account for
approximately one-third of US individuals, can be treated with much higher atomoxetine doses than those
recommended in the package insert, as long as atomoxetine TDM demonstrates safe steady-state trough
concentrations similar to those seen in CYP2D6 PMs with recommended doses.
In summary, clinicians may need to be aware that normal atomoxetine doses may not be enough
for CYP2D6 UMs3 and possibly for CYP2D6 EMs ≥2 active alleles. As a matter of fact, in 2011 The
Royal Dutch Association for the Advancement of Pharmacy’s CYP genotyping guidelines concurred that
dosing atomoxetine in CYP2D6 UMs is problematic and recommended that clinicians “be alert to reduced
efficacy or select alternative drugs.” Researchers interested in studying patients who do not respond to
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atomoxetine have the challenge of building a new database by combining the concepts of CYP2D6
genotyping, atomoxetine TDM and wide therapeutic index.
THE DIFICULTIES OF IMPLEMENTING PERSONALIZED MEDICINE
Atomoxetine exemplifies why personalized medicine and pharmacogenetic testing are not widely
used in 2015 by child psychiatrists or physicians in general. Personalizing prescription is a complex
pharmacological puzzle that 1) can focus on drug dosing or drug selection; 2) requires combining genetics,
environmental and personal variables; and 3) necessitates understanding pharmacokinetic and
pharmacodynamic mechanisms in order to predict efficacy and safety. If one focuses on dosing, one also
needs to consider the drug’s therapeutic index. As a matter of fact, as each patient is a “unique individual”
with different drug responses governed by pharmacological laws, each drug may also be a “different
individual” governed by its specific pharmacological mechanisms.
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a

Table 1.Comparing atomoxetine response rate of CYP2D6 PMs to EMs
RCT dose
PMs

EMs

N

30

559

Response rate

80%

Dropouts due to lack of efficacy

18%

Predictions if dose is 10 times higher
Difference

EMs

60%

20%b

80%

27%

-9%c

18%

CI: 95% confidence interval; EM: extensive metabolizer; PM: poor metabolizer; OR: odds ratio; RCT: randomized clinical
trial.
a

At the endpoint of the acute treatment phase.

b

This difference was described as significant (p=0.033).5 The author estimated an OR comparing PMs vs. EMs of 2.7, CI, 1.3-

5.9.
c

This difference was described as significant (p=0.004).5 The OR comparing PMs vs. EMs was 0.57, CI, 0.40-0.79.

